Patients with PV tend to be very symptomatic, but Jakafi can help.
BY Jeanne M. Palmer, M.D.
PUBLISHED April 10, 2018
Jeanne M. Palmer, M.D., hematologist oncologist at the Mayo Clinic in Arizona discusses the benefit of Jakafi (ruxolitinib) for patients with polycythemia vera (PV) – a type of myeloproliferative neoplasm.
Patients with PV tend to be very symptomatic, and Jakafi provides good symptom control compared to some other PV treatments that have their own set of risks and side effects.